Comprehensive Management of Upper Tract Urothelial Carcinoma

Call for Papers

Urothelial carcinoma of the upper urinary tract is relatively uncommon, representing only 5% of all urothelial cancers. The 5-year cancer-specific survival for upper tract urothelial carcinoma in the United States is roughly 75% with grade and stage serving as the most powerful predictors of survival. Nephroureterectomy with excision of the ipsilateral ureteral orifice and bladder cuff en bloc remains the gold standard treatment for upper tract urothelial carcinoma, but endoscopic and laparoscopic approaches, are rapidly evolving as standards of care depending on grade and stage of disease. Several controversies remain in management of upper tract urothelial carcinoma including patient selection for endoscopic versus laparoscopic approaches, management strategies of the distal ureter, the role of lymphadenectomy in upper tract urothelial carcinoma, and the value of chemotherapy in upper tract disease.

Aims of this special edition will be to critically review and evaluate controversies in management of upper tract urothelial cancer including: endoscopic management of upper tract urothelial carcinoma, laparoscopic nephroureterectomy and management of the distal ureter, the role of lymphadenectomy in management of upper tract urothelial cancer, and the emerging role of chemotherapy in upper tract disease.

Authors should follow the Advances in Urology manuscript format described at the journal site http://www.hindawi.com/journals/au/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/, according to the following timetable:

Manuscript Due	May 1, 2008
First Round of Reviews	August 1, 2008
Publication Date	November 1, 2008

Guest Editor

• Norm D. Smith, Department of Urology, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Tarry 16-703, Chicago, IL 60611-3008, USA